Doctolib Raises $324M in Secondary Share Sale to Strüngmann Family Office ATHOS KG, A.P. Moller Holding, and Generation Investment Management

Why It Matters

The devaluation illustrates how rising interest rates and post‑pandemic demand normalization are reshaping European health‑tech valuations, while Doctolib’s strategic pivot highlights the path to profitability that investors now demand.

Key Takeaways

• Valuation dropped 40% to $4 bn amid market multiple compression.
• ARR grew 50% to $465 million, yet multiples fell to 8.5×.
• Secondary sale brought $330 million from institutional investors.
• Telemedicine usage stabilised at 4‑6% post‑pandemic.
• AI platform targets profitability ahead of 2026 IPO.

Pulse Analysis

The drop in Doctolib’s market value from €5.8 billion ($6.4 billion) to €3.6 billion ($4 billion) mirrors a broader correction in European health‑tech equities. Rising interest rates have forced investors to apply steeper discount rates, compressing SaaS revenue multiples from roughly 20× to under 9×. In addition, the €300 million ($330 million) secondary share sale was priced at a typical 10‑30% liquidity discount, reflecting the lower risk tolerance of institutional buyers compared with early‑stage venture capital. Together, these forces explain why a company with expanding revenue can see its headline valuation shrink dramatically.

Despite the valuation dip, Doctolib’s operational metrics remain robust. Annual recurring revenue climbed to €422 million ($465 million), pushing the revenue‑multiple to about 8.5× while the company narrowed its adjusted EBITDA loss from €87 million to €54 million in a single year. A 2024 investment of €115 million ($127 million) in AI‑driven tools—such as an ambient‑scribe that automates clinical documentation—has positioned the platform as a full‑stack healthcare operating system. This strategic shift aims to hit the Rule‑of‑40 benchmark, pairing 20%+ growth with breakeven EBITDA ahead of a projected 2026 IPO.

The Doctolib case offers a template for European health‑tech firms navigating a post‑pandemic, high‑rate environment. Investors now reward companies that have secured EU AI Act and MDR compliance, granting a 20‑30% valuation premium for regulatory moats. At the same time, the market favors clear paths to profitability and scalable subscription models, pressuring firms to demonstrate EBITDA positivity before listing. Whether Doctolib chooses a Nasdaq debut or remains on Euronext will hinge on the relative multiple uplift—potentially 20‑30%—that a US listing can command. The outcome will shape capital expectations for the next wave of digital‑health IPOs across Europe.

Deal Summary

Doctolib completed a $324 million secondary share sale, selling shares from long‑term employees and early angel investors to new institutional backers including Strüngmann family office ATHOS KG, A.P. Moller Holding, and Generation Investment Management. The transaction values the company at about $3.9 billion, a 40 % drop from its $6.3 billion peak in 2022, and provides liquidity to early shareholders while bringing industrial‑grade investors to its cap table.